This is investment research, not personal financial advice.

Innate Pharma (EURONEXT-PARIS:IPH) closed at €1.832 on 10 August, up 21.49%, after Sobi agreed to license lacutamab and fund the next step toward Phase III. The move is broadly proportionate to the financing relief. It does not validate the drug, and it should not be read as if the full $580m headline were cash in the bank.

The fixed payment answers an urgent question

In May, Innate reported €25.4m of cash and financial assets at 31 March and said that amount funded operations only through the end of the third quarter. It also made TELLOMAK-3's planned H2 2026 start conditional on finding non-dilutive financing (Innate Pharma 2026b).

The Sobi agreement supplies that missing bridge. Sobi will pay $75m when the transaction closes, subject to conditions including antitrust clearance. Innate will run the confirmatory TELLOMAK-3 study; Sobi receives exclusive global commercial rights if lacutamab reaches accelerated approval, then can assume full development rights after positive Phase III results (Innate Pharma 2026a).

At the ECB's 10 August reference rate of $1.1555 per euro, the fixed payment equals about €64.9m. That is 2.56 times Innate's March cash position. Before trial spending, it would lift the two amounts combined to roughly €90.3m (ECB 2026; Innate Pharma 2026b).

Most of the $580m remains conditional

The transaction totals $580m only if every milestone lands. Only $75m, or 12.9% of the stated maximum, is payable at closing. A further $40m depends on near-term Sézary syndrome development milestones. The remaining $465m covers Sobi's option to take full development rights plus future regulatory and commercial milestones. Innate also retains tiered double-digit royalties on net sales (Innate Pharma 2026a).

That structure transfers part of the financing burden without transferring the clinical risk. Lacutamab still has to start TELLOMAK-3, generate positive progression-free-survival data and clear regulators. Independent coverage also points to recent CTCL setbacks, including an EMA rejection for resminostat and Soligenix ending a Phase III programme after a monitoring committee judged success unlikely (Pharmaceutical Technology 2026).

The market paid for lower financing risk

Using 93.934m shares reported by Innate and the €1.832 close, market capitalisation was about €172.09m after the move. The prior close implied €141.65m, so the session added roughly €30.43m of equity value. That is less than half the €64.9m converted value of the closing payment (Euronext 2026; Innate Pharma 2026c; ECB 2026).

The €34.48m difference leaves room for closing risk, trial spending and ongoing cash burn. The tape has repriced near-term dilution risk more than lacutamab's probability of approval. On that basis, the 21.49% rise looks proportionate: fixed cash is large against the old cash base, while most deal value depends on evidence that has not arrived.

Closing is the next test, followed by TELLOMAK-3 initiation in H2 2026. Those disclosures will show whether the agreement bought only time or also kept the development timetable intact.

References